- Home
- BCTX vs EDUC Comparison
BCTX vs EDUC Comparison
Compare BCTX & EDUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- EDUC
- Stock Information
- Founded
- BCTX 2014
- EDUC 1965
- Country
- BCTX Canada
- EDUC United States
- Employees
- BCTX N/A
- EDUC N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- EDUC Consumer Specialties
- Sector
- BCTX Health Care
- EDUC Consumer Discretionary
- Exchange
- BCTX Nasdaq
- EDUC Nasdaq
- Market Cap
- BCTX 17.2M
- EDUC 16.6M
- IPO Year
- BCTX N/A
- EDUC N/A
- Fundamental
- Price
- BCTX $0.79
- EDUC $1.82
- Analyst Decision
- BCTX Strong Buy
- EDUC
- Analyst Count
- BCTX 1
- EDUC 0
- Target Price
- BCTX $15.00
- EDUC N/A
- AVG Volume (30 Days)
- BCTX 690.7K
- EDUC 6.9K
- Earning Date
- BCTX 12-12-2024
- EDUC 01-09-2025
- Dividend Yield
- BCTX N/A
- EDUC N/A
- EPS Growth
- BCTX N/A
- EDUC N/A
- EPS
- BCTX N/A
- EDUC N/A
- Revenue
- BCTX N/A
- EDUC $42,415,800.00
- Revenue This Year
- BCTX N/A
- EDUC N/A
- Revenue Next Year
- BCTX N/A
- EDUC N/A
- P/E Ratio
- BCTX N/A
- EDUC N/A
- Revenue Growth
- BCTX N/A
- EDUC N/A
- 52 Week Low
- BCTX $0.46
- EDUC $0.80
- 52 Week High
- BCTX $5.97
- EDUC $2.95
- Technical
- Relative Strength Index (RSI)
- BCTX 55.70
- EDUC 30.95
- Support Level
- BCTX $0.57
- EDUC $1.87
- Resistance Level
- BCTX $0.74
- EDUC $2.11
- Average True Range (ATR)
- BCTX 0.06
- EDUC 0.09
- MACD
- BCTX 0.00
- EDUC -0.01
- Stochastic Oscillator
- BCTX 88.08
- EDUC 12.12
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.